ClinicalTrials.gg
CompletedNCT05981846Updated Nov 17, 2026

A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19

A Phase 2 interventional study of BIMERVAX and SIIV in SARS CoV 2 Infection and Influenza, Human, sponsored by Hipra Scientific, S.L.U. Completed at 8 sites in Spain. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Hipra Scientific, S.L.U · Phase 2, Interventional, and Prevention

How we know

Updated Nov 17, 2026Primary completion movedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
279
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 401 studies in COVID-19 with a site in Spain — 25 open to participants now, 32 under way, 7 of them phase 3. COVID-19 · Spain.

Enrollment
85th of 254
279 · median 132
Started
2023
with 21 others
Phase 2
54 of 401
1 open now
Registered
370th of 401
by date
Lead sponsor
7 of 401
Hipra Scientific, S.L.U

Among the 401 studies in COVID-19 with a site in Spain, this one is the 85th largest by enrollment of the 254 interventional ones that give a count, is one of 22 that started in 2023, is one of 54 in phase 2, and was the 370th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

25 of the 401 studies in COVID-19 with a site in Spain are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 401 studies in COVID-19 with a site in Spain, or all of them as a file.
02

Study summary

This is a Phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX® when coadministered with seasonal surface antigen inactivated adjuvanted influenza vaccine (SIIV) in adults older than 65 years of age fully vaccinated against COVID-19.

Read the detailed description

This is a Phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX® when coadministered with seasonal surface antigen inactivated adjuvanted influenza vaccine (SIIV) in adults older than 65 years of age fully vaccinated against COVID-19.

In this study approximately 300 adults aged 65 or older will be enrolled and followed for 1 month after study treatment. Safety and immunogenicity of all participants will be assessed.

The participants will be randomised 1:1:1 to one of the following three cohorts:

  • Cohort 1: approximately 100 participants will receive one dose of SIIV in one arm + one dose of placebo in the other arm, at Day 0.
  • Cohort 2: approximately 100 participants will receive one dose of BIMERVAX® in one arm + 1 dose of placebo in the other arm, at Day 0.
  • Cohort 3: approximately 100 participants will receive one dose SIIV in one arm + one dose of BIMERVAX® in the other arm, at Day 0.

All participants will receive two administrations at Day 0 and will be followed for 1 month. All subjects will be closely observed for 15 minutes after vaccination on site. The study will be double-blind, both the participant and the physician (care provider) will be blinded. Participants will be provided with a participant paper diary on Day 0 to record solicited local and systemic reactions after vaccination through Day 7. Unsolicited local and systemic adverse events, SAEs and AESIs, will be recorded through Day 28 (end of study).

03

Conditions studied

  • SARS CoV 2 Infection
  • Influenza, Human
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged 65 or older at Day 0.
  2. Are willing and able to sign the and can comply with all study visits and procedures.
  3. Participant must have received at least a primary scheme of an mRNA vaccine (2 doses). Booster doses or previous COVID-19 infections are allowed. Last dose must have been administered at least 6 months before Day 0. History of COVID-19 infection is allowed if occurred at least >30 days before Day 0.
  4. Have a negative Rapid Antigen Test (RAT) at Day 0 before vaccinations.
  5. Adults determined by clinical assessment, including medical history and clinical judgement, to be eligible for the study, including adults with pre-existing chronic and stable diseases (non-), if these are stable and well-controlled according to the investigator's judgment.

Exclusion criteria

Exclusion Criteria:

  1. Acute illness with fever ≥ 38.0°C at Day 0 or within 24 hours prior to vaccination. Afebrile participants with minor illnesses can be enrolled at the discretion of the investigator.
  2. Allergy to egg proteins (egg or egg products) or chicken proteins.
  3. History of Guillain-Barré syndrome (GBS)
  4. History of COVID-19 infection (described as a positive RAT or PCR), in the previous 30 days before Day 0.
  5. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behaviour that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  6. History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (e.g. anaphylaxis) to any component of the study intervention(s).
  7. individuals defined as those with primary and secondary immune deficiencies and those receiving chemotherapy or immunosuppressant drugs other than and glucocorticoids (maximum 30mg/day of prednisone, or equivalent, by any administration route for a maximum of 30 consecutive days), within 90 days prior to vaccination or during the study.
  8. Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
  9. Receipt of blood-derived immune globulins, blood, or blood-derived products in the past 3 months.
  10. Participation in other studies involving study intervention within 28 days prior to screening and/or during study participation.
  11. Received any non-study vaccine within 14 days before or after screening. For live or attenuated vaccines, 4 weeks before or after screening.
  12. History of a diagnosis or other conditions that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
279 participants (actual)

Study arms

  • Experimental
    BIMERVAX + SIIV

    Biological: BIMERVAX · Biological: SIIV

  • Active comparator
    BIMERVAX + PLACEBO

    Biological: BIMERVAX

  • Active comparator
    SIIV + PLACEBO

    Biological: SIIV

Interventions

  • BiologicalBIMERVAX

    One dose of booster vaccine

  • BiologicalSIIV

    One dose

06

What researchers measure

Primary outcomes

  1. Number, percentage, and characteristics of solicited local and systemic reactions through Day 7 after vaccination.

    To assess and compare the safety and tolerability of BIMERVAX® coadministered with SIIV in adults with respect to each vaccine administered alone.

    Time frame: Day 0, Day 7

  2. Number, percentage, and characteristics of unsolicited local and systemic adverse events (AEs) through the end of the study.

    To assess and compare the safety and tolerability of BIMERVAX® coadministered with SIIV in adults with respect to each vaccine administered alone.

    Time frame: Day 0, Day 7, Day 28

  3. Number and percentage of serious adverse events (SAEs) through the end of the study.

    To assess and compare the safety and tolerability of BIMERVAX® coadministered with SIIV in adults with respect to each vaccine administered alone.

    Time frame: Day 0, Day 7, Day 28

  4. Number and percentage of adverse events of special interest (AESI) through the end of the study

    To assess and compare the safety and tolerability of BIMERVAX® coadministered with SIIV in adults with respect to each vaccine administered alone.

    Time frame: Day 0, Day 7, Day 28

Secondary outcomes

  1. Total binding antibody titers against SARS-CoV-2 RBD at Days 0 and 28

    To determine and compare the immunogenicity measured by means of total antibodies against the Receptor Binding Domain of the Spike protein of SARS-CoV-2, measured by an electrochemiluminescence immunoassay (ECLIA) at Baseline and Day 28, in participants vaccinated with BIMERVAX® alone or coadministered with SIIV.

    Time frame: Day 0, Day28

  2. Geometric mean fold rise in total binding antibody titers against SARS-CoV-2 RBD at Day 28

    To determine and compare the geometric mean fold rise (GMFR) in total binding antibody titers against the Receptor Binding Domain of the Spike protein of SARS-CoV-2 from Baseline to Day 28, in participants vaccinated with BIMERVAX® alone or coadministered with SIIV.

    Time frame: Day 0, Day28

  3. Influenza strain-specific HAI antibody titers at Days 0 and 28

    To determine and compare the immunogenicity measured by influenza strain-specific antibody titers using a haemagglutination inhibition (HAI) assay at Baseline and Day 28, in participants vaccinated with SIIV alone or coadministered with BIMERVAX®

    Time frame: Day 0, Day28

  4. Geometric mean fold rise in influenza strain-specific HAI antibody titers at Day 28

    To determine and compare the geometric mean fold rise (GMFR) in influenza strain-specific antibody titers measured by haemagglutination inhibition (HAI) assay from Baseline to Day 28, in participants vaccinated with SIIV alone or coadministered with BIMERVAX®.

    Time frame: Day 0, Day28

07

Study locations

8 sites
  • Hospital HM Modelo
    A Coruña, A Coruña 15011, Spain
  • Hospital Clínico Universitario de Santiago
    Santiago de Compostela, A Coruña 15706, Spain
  • Hospital Germans Trias i Pujol
    Badalona, Barcelona 08916, Spain
  • Hospital Clínic de Barcelona
    Barcelona, Barcelona 08036, Spain
  • CAP Centelles
    Centelles, Barcelona 08540, Spain
  • Hospital Josep Trueta
    Girona, Girona 17001, Spain
  • Hospital Regional de Málaga
    Málaga, Málaga 29010, Spain
  • Hospital Clínico de Valladolid
    Valladolid, Valladolid 47003, Spain
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Nov 2023, 1 month.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 1 month is below that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2023 → Nov 2023, on Nov 17, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2023
First posted
Aug 8, 2023
StartActual
Sep 4, 2023
Primary completionActual
Nov 3, 2023was Oct 2023
CompletionActual
Nov 3, 2023
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites added, 6 sites removed
Show 6 added (6 Spain)
  • Hospital HM Modelo · A Coruña, Spain
  • Hospital Clínico Universitario de Santiago · Santiago de Compostela, Spain
  • Hospital Clínic de Barcelona · Barcelona, Spain
  • Hospital Josep Trueta · Girona, Spain
  • Hospital Regional de Málaga · Málaga, Spain
  • Hospital Clínico de Valladolid · Valladolid, Spain
Show 6 removed
  • Hospital Clínico Universitario de Santiago · Santiago De Compostela, Spain
  • Hospital HM Modelo · A Coruña, Spain
  • Hospital Clínic de Barcelona · Barcelona, Spain
  • Hospital Josep Trueta · Girona, Spain
  • Hospital Regional de Málaga · Málaga, Spain
  • Hospital Clínico de Valladolid · Valladolid, Spain
Nov 17, 2026
Primary completion
Oct 9, 2023→Nov 3, 2023
Nov 17, 2026
Study completion
Nov 6, 2023→Nov 3, 2023
Nov 17, 2026
Primary outcomes
4 description edited
What changed in the outcomes
  • DescriptionNumber and percentage of adverse events of special interest (AESI) through the end of the study: how it is measured was reworded
  • DescriptionNumber and percentage of serious adverse events (SAEs) through the end of the study.: how it is measured was reworded
  • DescriptionNumber, percentage, and characteristics of solicited local and systemic reactions through Day 7 after vaccination.: how it is measured was reworded
  • DescriptionNumber, percentage, and characteristics of unsolicited local and systemic adverse events (AEs) through the end of the study.: how it is measured was reworded
Nov 17, 2026
Secondary outcomes
4 added
What changed in the outcomes
  • AddedTotal binding antibody titers against SARS-CoV-2 RBD at Days 0 and 28Time frame: Day 0, Day28
  • AddedGeometric mean fold rise in total binding antibody titers against SARS-CoV-2 RBD at Day 28Time frame: Day 0, Day28
  • AddedInfluenza strain-specific HAI antibody titers at Days 0 and 28Time frame: Day 0, Day28
  • AddedGeometric mean fold rise in influenza strain-specific HAI antibody titers at Day 28Time frame: Day 0, Day28
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    6 sites added, 6 sites removed
    Show 6 added (6 Spain)
    • Hospital HM Modelo · A Coruña, Spain
    • Hospital Clínico Universitario de Santiago · Santiago de Compostela, Spain
    • Hospital Clínic de Barcelona · Barcelona, Spain
    • Hospital Josep Trueta · Girona, Spain
    • Hospital Regional de Málaga · Málaga, Spain
    • Hospital Clínico de Valladolid · Valladolid, Spain
    Show 6 removed
    • Hospital Clínico Universitario de Santiago · Santiago De Compostela, Spain
    • Hospital HM Modelo · A Coruña, Spain
    • Hospital Clínic de Barcelona · Barcelona, Spain
    • Hospital Josep Trueta · Girona, Spain
    • Hospital Regional de Málaga · Málaga, Spain
    • Hospital Clínico de Valladolid · Valladolid, Spain
    Primary completion Oct 9, 2023→Nov 3, 2023
    Study completion Nov 6, 2023→Nov 3, 2023
    Primary outcomes 4 description edited
    What changed in the outcomes
    • DescriptionNumber and percentage of adverse events of special interest (AESI) through the end of the study: how it is measured was reworded
    • DescriptionNumber and percentage of serious adverse events (SAEs) through the end of the study.: how it is measured was reworded
    • DescriptionNumber, percentage, and characteristics of solicited local and systemic reactions through Day 7 after vaccination.: how it is measured was reworded
    • DescriptionNumber, percentage, and characteristics of unsolicited local and systemic adverse events (AEs) through the end of the study.: how it is measured was reworded
    Secondary outcomes 4 added
    What changed in the outcomes
    • AddedTotal binding antibody titers against SARS-CoV-2 RBD at Days 0 and 28Time frame: Day 0, Day28
    • AddedGeometric mean fold rise in total binding antibody titers against SARS-CoV-2 RBD at Day 28Time frame: Day 0, Day28
    • AddedInfluenza strain-specific HAI antibody titers at Days 0 and 28Time frame: Day 0, Day28
    • AddedGeometric mean fold rise in influenza strain-specific HAI antibody titers at Day 28Time frame: Day 0, Day28
    + 3 other changes: verification date, description and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05981846
Lead sponsor
Hipra Scientific, S.L.U
Responsible party
Sponsor
First posted
Aug 8, 2023
Start date
Sep 4, 2023
Primary completion
Nov 3, 2023
Completion
Nov 3, 2023
Last update
Nov 17, 2026

Study contacts

Teresa Prat
study director · Hipra Scientific, S.L.U

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion